NASDAQ:VBIV

VBI Vaccines (VBIV) Stock Forecast, Price & News

$0.67

+0.04 (+6.81%)

(As of 05:19 PM ET)

Compare

Today's Range: $0.66
▼
$0.74
50-Day Range: $0.61
▼
$1.50
52-Week Range: $0.59
▼
$23.70

Volume: 1.95 million shs
Average Volume: 530,276 shs
Market Capitalization: $15.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.00

VBI Vaccines MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5,672.0% Upside
$40.00 Price Target
Short Interest: Healthy
0.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.74
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$1 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.46) to ($1.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

79th out of 963 stocks

Pharmaceutical Preparations Industry

21st out of 451 stocks

3.5

Analyst's Opinion

Consensus Rating
VBI Vaccines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.00, VBI Vaccines has a forecasted upside of 5,672.0% from its current price of $0.69.
Amount of Analyst Coverage
VBI Vaccines has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.79% of the float of VBI Vaccines has been sold short.
Short Interest Ratio / Days to Cover
VBI Vaccines has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VBI Vaccines has recently increased by 28.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
VBI Vaccines does not currently pay a dividend.
Dividend Growth
VBI Vaccines does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
VBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for VBI Vaccines is -0.75.

3.2

News and Social Media Coverage

News Sentiment
VBI Vaccines has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for VBI Vaccines this week, compared to 1 article on an average week.
Search Interest
6 people have searched for VBIV on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
5 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VBI Vaccines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,004,998.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.35% of the stock of VBI Vaccines is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 19.08% of the stock of VBI Vaccines is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for VBI Vaccines are expected to grow in the coming year, from ($2.46) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VBI Vaccines is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VBI Vaccines has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About VBI Vaccines (NASDAQ:VBIV) Stock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

VBIV Price History

30 days | 90 days | 365 days | Advanced Chart

VBIV Stock News Headlines

September 27, 2023 | msn.com

VBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concern

September 27, 2023 | markets.businessinsider.com

VBI Vaccines To Advance Coronavirus Vaccine Program

September 27, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 27, 2023 | finance.yahoo.com

VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

September 21, 2023 | americanbankingnews.com

VBI Vaccines (NASDAQ:VBIV) Share Price Crosses Below Two Hundred Day Moving Average of $2.77

September 7, 2023 | finance.yahoo.com

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

September 6, 2023 | msn.com

VBI Vaccines gains after Phase 2 data for Hep B candidate

September 6, 2023 | finance.yahoo.com

VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B

September 27, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 14, 2023 | seekingalpha.com

VBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M misses by $0.19M

August 14, 2023 | finance.yahoo.com

VBI Vaccines Reports Second Quarter 2023 Financial Results

July 24, 2023 | finance.yahoo.com

VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares

July 19, 2023 | finance.yahoo.com

7 Biotech Stocks to Sell in July

July 10, 2023 | bizjournals.com

Durham biotech secures global rights to hepatitis B treatment

July 6, 2023 | msn.com

VBI Vaccines Stock Cut in Half after Announcing Public Offering

July 6, 2023 | finance.yahoo.com

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

July 6, 2023 | investorplace.com

Why Is VBI Vaccines (VBIV) Stock Down 40% Today?

July 6, 2023 | benzinga.com

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

July 6, 2023 | msn.com

VBI Vaccines, Brii Biosciences Expand Hepatitis B Immunotherapy Pact

July 5, 2023 | seekingalpha.com

VBI Vaccines down 3% after hours on public offering

July 5, 2023 | businesswire.com

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus ...

July 5, 2023 | finance.yahoo.com

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

July 5, 2023 | finance.yahoo.com

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

June 25, 2023 | finance.yahoo.com

Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

June 15, 2023 | finance.yahoo.com

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

June 7, 2023 | finance.yahoo.com

VBI Vaccines Announces Poster Presentation at EASL 2023

June 4, 2023 | finance.yahoo.com

VBI Vaccines Inc.'s (NASDAQ:VBIV) Intrinsic Value Is Potentially 30% Above Its Share Price

See More Headlines

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VBIV
CUSIP: N/A
CIK: 764195
Web: www.vbivaccines.com
Phone: (617) 830-3031
Fax: N/A
Employees: 190
Year Founded: 2001

Price Target and Rating

Average Stock Price Forecast: $40.00
High Stock Price Forecast: $40.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +5,651.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($13.6754)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,300,000.00
Net Margins: -6,541.54%
Pretax Margin: -6,541.54%
Return on Equity: -165.08%
Return on Assets: -61.23%

Debt

Debt-to-Equity Ratio: 5.47
Current Ratio: 1.15
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $1.08 million
Price / Sales: 14.73
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.46 per share
Price / Book: 0.09

Miscellaneous

Outstanding Shares: 22,870,000
Free Float: 20,505,000
Market Cap: $15.91 million
Optionable: Optionable
Beta: 1.81

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Jeffery R. Baxter FCMA (Age 62)
Pres, CEO & Director
Comp: $908.06k

Dr. David Evander Anderson (Age 53)
Chief Scientific Officer
Comp: $534.25k

Dr. Francisco Diaz-Mitoma FRCPC (Age 68)
M.D., Ph.D., Chief Medical Officer
Comp: $544.52k

Ms. Nell Beattie (Age 35)
CFO, Head of Corp. Devel. & Director

Nicole Anderson
Director of Corp. Communications & Investor Relations

Ms. Athena Kartsaklis (Age 58)
Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer

Mr. Avi Mazaltov (Age 61)
Global Head of Manufacturing & GM of SciVac

Mr. Misha Nossov
Sr. VP of Global Commercial Supply Strategy & Head of Europe

Mr. T. Adam Buckley (Age 47)
Sr. VP of Bus. Devel.

Mr. John Robert Dillman (Age 55)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VBIV Stock - Frequently Asked Questions

Should I buy or sell VBI Vaccines stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VBIV shares.
View VBIV analyst ratings or view top-rated stocks.
What is VBI Vaccines' stock price forecast for 2023?: 1 Wall Street analysts have issued 1-year price targets for VBI Vaccines' stock. Their VBIV share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 5,651.3% from the stock's current price.
View analysts price targets for VBIV or view top-rated stocks among Wall Street analysts.
How have VBIV shares performed in 2023?: VBI Vaccines' stock was trading at $7.8220 at the start of the year. Since then, VBIV shares have decreased by 91.1% and is now trading at $0.6955.
View the best growth stocks for 2023 here.
Are investors shorting VBI Vaccines?: VBI Vaccines saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 169,600 shares, an increase of 28.5% from the August 31st total of 132,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.8% of the company's stock are short sold.
View VBI Vaccines' Short Interest.
When is VBI Vaccines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VBIV earnings forecast.
How were VBI Vaccines' earnings last quarter?: VBI Vaccines Inc. (NASDAQ:VBIV) announced its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.16) by $0.01. The biopharmaceutical company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $1.46 million. VBI Vaccines had a negative net margin of 6,541.54% and a negative trailing twelve-month return on equity of 165.08%.
When did VBI Vaccines' stock split?: VBI Vaccines's stock reverse split on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of VBI Vaccines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().
What is VBI Vaccines' stock symbol?: VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
Who are VBI Vaccines' major shareholders?: VBI Vaccines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (6.04%), BlackRock Inc. (0.49%), Cambridge Investment Research Advisors Inc. (1.17%), Geode Capital Management LLC (0.29%), General American Investors Co. Inc. (0.27%) and Y Intercept Hong Kong Ltd (0.17%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc and Steven Gillis.
View institutional ownership trends.
How do I buy shares of VBI Vaccines?: Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is VBI Vaccines' stock price today?: One share of VBIV stock can currently be purchased for approximately $0.70.
How much money does VBI Vaccines make?: VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $15.91 million and generates $1.08 million in revenue each year. The biopharmaceutical company earns $-113,300,000.00 in net income (profit) each year or ($13.6754) on an earnings per share basis.
How many employees does VBI Vaccines have?: The company employs 190 workers across the globe.
How can I contact VBI Vaccines?: VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for the company is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com.

This page (NASDAQ:VBIV) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial